Minimal Residual Disease as a Surrogate Marker for Risk Assignment to ALL Patients

Reviews in Clinical and Experimental Hematology

Volumn 7, Issue 3, 2003, Pages 292-323

  Cazzaniga, Giovanni ^a   Gaipa, Giuseppe ^a   Rossi, Vincenzo ^a   Biondi, Andrea ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE LYMPHOCYTIC LEUKEMIA; CANCER REGRESSION; DISEASE MARKER; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA CELL; MINIMAL RESIDUAL DISEASE; POLYMERASE CHAIN REACTION; RECURRENCE RISK; REMISSION; REVIEW; TREATMENT OUTCOME;

CHILD; CLINICAL TRIALS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; RISK ASSESSMENT; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 0346394011     PISSN: 11270020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (118)

1. Pui CH, Campana D and Evans WE. Childhood acute lymphoblastic leukemia: current status and future perspectives. Lancet Oncol, 2: 597-607, 2001.
2. Van Bekkum DW. Reflection on the detection and treatment of leukaemia. In: Minimal residual disease in acute leukaemia. Ed. Lowenberg B and Hagenbeek A. Martinus Nijhoff, Boston, pp 385-90, 1984.
3. Campana D. Determination of minimal residual disease in leukaemia patients. Br J Haematol, 121: 823-838, 2003.
4. Szczepanski T, Orfao A, van der Velden VH, et al. Minimal residual disease in leukaemia patients. Lancet Oncol, 2: 409-417, 2001.
5. Cazzaniga G and Biondi A. Molecular monitoring of minimal residual disease. In: Treatment of acute leukemias: new directions for clinical research. Ed. Pui C-H. Humana press, Totowa, NJ, pp 537-547, 2003.
6. Pui CH and Campana D. New definition of remission in childhood acute lymphoblastic leukemia. Leukemia, 14: 783-785, 2000.
7. Mathe G, Schwarzenberg L, Mery AM, et al. Extensive histological and cytological survey of patients with acute leukaemia in 'complete remission'. Br Med J, 5488: 640-642, 1966
8. Martens AC, Schultz FW and Hagenbeek A. Nonhomogeneous distribution of leukemia in the bone marrow during minimal residual disease. Blood, 70: 1073-1078, 1987.
9. Harrison CJ and Foroni L. Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Rev Clin Exp Hematol, 6.2: 91-113, 2002.
10. Najfeld V, Burnett W, Vlachos A, et al. Interphase FISH analysis of sex-mismatched BMT utilizing dual color XY probes. Bone Marrow Transplant, 8: 829-834, 1997.
11. Loncarevic IF, Roitzheim B, Ritterbach J, et al. Trisomy 21 is a recurrent secondary aberration in childhood acute lymphoblastic leukemia with TEL/AML1 gene fusion. Genes Chromosomes Cancer, 24: 272-277, 1999.
12. Harrison CJ. Acute lymphoblastic leukaemia. Best Pract Res Clin Haematol, 14: 593-607, 2001.
13. Mathew S and Raimondi SC. FISH, CGH, and SKY in the diagnosis of childhood acute lymphoblastic leukemia. Methods Mol Biol, 220: 213-233, 2003.
14. Bielorai B, Golan H, Trakhtenbrot L, et al. Combined analysis of morphology and fluorescence in situ hybridization in follow-up of minimal residual disease in a child with Philadelphia-positive acute lymphoblastic leukemia. Cancer Genet Cytogenet, 138: 64-68, 2002.
15. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia, 13: 1901-1928, 1999.
16. Pongers-Willemse MJ, Seriu T, Stolz F, et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets. Leukemia, 13: 110-118, 1999.
17. Lucio P, Parreira A, van den Beemd MW, et al. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia, 13: 419-427, 1999.
18. Campana D and Coustan-Smith E. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol, 15: 1-19, 2002.
19. Dworzak MN, Froschl G, Printz D, et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood, 99: 1952-1958, 2002.
20. Campana D and Pui CH. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood, 85: 1416-1434, 1995.
21. Van Dongen JJM, Szczepanski T, de Bruijn MAC, et al. Detection of minimal residual disease in acute leukemia patients. Cytokines Mol Ther, 2: 121-133, 1996.
22. Porwit-MacDonald A, Bjorklund E, Lucio P, et al. BIOMED-1 concerted action report: flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL). Leukemia, 14: 816-825, 2000.
23. Campana D and Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry, 38: 139-152, 1999.
24. Pui CH, Raimondi SC, Head DR, et al. Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. Blood, 78: 1327-1337, 1991.
25. Abshire TC, Buchanan GR, Jackson JF, et al. Morphologic, immunologic and cytogenetic studies in children with acute lymphoblastic leukemia at diagnosis and relapse: a Pediatric Oncology Group study. Leukemia, 6: 357-362, 1992.
26. Baer MR, Stewart CC, Dodge RK, et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood, 97: 3574-3580, 2001.
27. van Wering ER, Beishuizen A, Roeffen ET, et al. Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia. Leukemia, 9: 1523-1533, 1995.
28. Macedo A, San Miguel JF, Vidriales MB, et al. Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease. J Clin Pathol, 49: 15-18, 1996.
29. Chen J-S, Coustan-Smith E, Hsiao CC, et al. Studies of minimal residual disease by flow cytometry in childhood acute lymphoblastic leukemia: application of a novel approach for data analysis and quality control. Hematol J, 4 (suppl.2): 119a, 2003.
30. Rabbitts TH. Chromosomal translocations in human cancer. Nature, 372: 143-149, 1994.
31. Look AT. Oncogenic transcription factors in the human acute leukemias. Science, 278: 1059-1064, 1997.
32. Breit TM, Beishuizen A, Ludwig WD, et al. tal-1 deletions in T-cell acute lymphoblastic leukemia as PCR target for detection of minimal residual disease. Leukemia, 7: 2004-2011, 1993.
33. Carlotti E, Pettenella F, Amaru R, et al. Molecular characterization of a new recombination of the SIL/TAL-1 locus in a child with T-cell acute lymphoblastic leukaemia. Br J Haematol, 118: 1011-1018, 2002.
34. Akasaka T, Muramatsu M, Ohno H, et al. Application of long-distance polymerase chain reaction to detection of junctional sequences created by chromosomal translocation in mature B-cell neoplasms. Blood, 88: 985-994, 1996.
35. Reichel M, Gillert E, Breitenlohner I, et al. Rapid isolation of chromosomal breakpoints from patients with t(4;11) acute lymphoblastic leukemia: implications for basic and clinical research. Leukemia, 15: 286-288, 2001.
36. Wiemels JL, Cazzaniga G, Daniotti M, et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet, 354: 1499-1503, 1999.
37. Basso K, Frascella E, Zanesco L, et al. Improved long-distance polymerase chain reaction for the detection of t(8;14)(q24;q32) in Burkitt's lymphomas. Am J Pathol, 155: 1479-1485, 1999.
38. zur Stadt U, Hoser G, Reiter A, et al. Application of long PCR to detect t(8;14)(q24;q32) translocations in childhood Burkitt's lymphoma and B-ALL. Ann Oncol, 8 (Suppl 1): 31-35, 1997.
39. Gessler M, Poustka A, Cavenee W, et al. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature, 343: 774-778, 1990.
40. Rosenfeld C, Cheever MA, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia, 17: 1301-1312, 2003.
41. Niegemann E, Wehner S, Kornhuber B, et al. wt1 gene expression in childhood leukemias. Acta Haematol 102: 72-76, 1999.
42. Cilloni D, Gottardi E, Messa F, et al. Piedmont Study Group on Myleodysplastic Syndromes. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol, 21: 1988-1995, 2003.
43. Bernard OA, Busson-LeConiat M, Ballerini P, et al. A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic. Leukemia, 15: 1495-1504, 2001.
44. Ballerini P, Blaise A, Busson-Le Coniat M, et al. HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis. Blood, 100: 991-997, 2002.
45. Steinbach D, Viehmann S, Zintl F, et al. PRAME gene expression in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet, 138: 89-91, 2002.
46. Janeway CA, Travers P, Walport M, et al. Immunobiology. 5th ed. Garland Publishing, New York and London, 2001.
47. van Dongen JJ and Wolvers-Tettero IL. Analysis of immunoglobulin and T cell receptor genes. Part II: possibilities and limitations in the diagnosis and management of lymphoproliferative diseases and related disorders. Clin Chim Acta, 198: 93-174, 1991.
48. Beishuizen A, De Bruijn MA, Pongers-Willemse MJ, et al. Heterogeneity in junctional regions of immunoglobulin kappa deleting element rearrangements in B cell leukemias: a new molecular target for detection of minimal residual disease. Leukemia, 11: 2200-2207, 1997.
49. Szczepanski T, Beishuizen A, Pongers-Willemse MJ, et al. Cross-lineage T cell receptor gene rearrangements occur in more than ninety percent of childhood precursor-B acute lymphoblastic leukemias: alternative PCR targets for detection of minimal residual disease. Leukemia, 13: 196-205, 1999.
50. Kneba M, Bolz I, Linke B et al. Analysis of rearranged T-cell receptor beta-chain genes by polymerase chain reaction (PCR) DNA sequencing and automated high resolution PCR fragment analysis. Blood, 86: 3930-3937, 1995.
51. Bottaro M, Berti E, Biondi A, et al. Heteroduplex analysis of T-cell receptor gamma gene rearrangements for diagnosis and monitoring of cutaneous T-cell lymphomas. Blood, 83: 3271-3278, 1994.
52. Landman-Parker J, Aubin J, Delabesse E, et al. Simplified strategies for minimal residual disease detection in B cell precursor acute lymphoblastic leukaemia. Br J Haematol, 95: 281-290, 1996.
53. Germano G, Songia S, Biondi A, et al. Rapid detection of clonality in patients with acute lymphoblastic leukemia. Haematologica, 86: 382-385, 2001.
54. Guidal C, Vilmer E, Grandchamp B, et al. A competitive PCR-based method using TCRD, TCRG and IGH rearrangements for rapid detection of patients with high levels of minimal residual disease in acute lymphoblastic leukemia. Leukemia, 16: 762-764, 2002.
55. Beishuizen A, Verhoeven MA, Van Wering ER, et al. Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis. Blood, 83: 2238-2247, 1994.
56. Szczepanski T, Willemse MJ, Brinkhof B, et al. Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood, 99: 2315-2323, 2002.
57. Germano G, del Giudice L, Palatron S, et al. Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring. Leukemia, 17: 1573-1582, 2003.
58. Peham M, Panzer S, Fasching K, et al. Low frequency of clonotypic Ig and T-cell receptor gene rearrangements in t(4;11) infant acute lymphoblastic leukaemia and its implication for the detection of minimal residual disease. Br J Haematol, 117: 315-321, 2002.
59. Brumpt C, Delabesse E, Beldjord K, et al. The incidence of clonal T-cell receptor rearrangements in B-cell precursor acute lymphoblastic leukemia varies with age and genotype. Blood, 96: 2254-2261, 2000.
60. van der Velden VH, Szczepanski T, Wijkhuijs JM, et al. Age-related patterns of immunoglobulin and T-cell receptor gene rearrangements in precursor-B-ALL: implications for detection of minimal residual disease. Leukemia, 17: 1834-1844, 2003.
61. Coustan-Smith E, Behm FG, Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet, 351: 550-554, 1998.
62. Vidriales MB, Perez JJ, Lopez-Berges MC, et al. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood, 101: 4695-4700, 2003.
63. Cazzaniga G, Rossi V, Biondi A. Monitoring minimal residual disease using chromosomal translocations in childhood ALL. Best Pract Res Clin Haematol, 15: 21-35, 2002.
64. Heid CA, Stevens J, Livak KJ, et al. Real time quantitative PCR. Genome Res, 6: 986-994, 1996.
65. van der Velden VH, Hochhaus A, Cazzaniga G, et al. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia, 17: 1013-1034, 2003.
66. Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia, 12: 2006-2014, 1998.
67. Verhagen OJ, Willemse MJ, Breunis WB, et al. Application of germline IgH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia, 14: 1426-1435, 2000.
68. Nakao M, Janssen JW, Flohr T, et al. Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology. Cancer Res, 60: 3281-3289, 2000.
69. Eckert C, Landt O, Taube T, et al. Potential of Light Cycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia, 14: 316-323, 2000.
70. Eckert C, Scrideli CA, Taube T, et al. Comparison between TaqMan and Lightcycler technologies for quantification of minimal residual disease by using immunoglobulin and T-cell receptor genes consensus probes. Leukemia, 2003 Oct 9 [Epub ahead of print].
71. Lyon E. Mutation detection using fluorescent hybridization probes and melting curve analysis. Expert Rev Mol Diagn, 1: 92-101, 2001.
72. Hochhaus A, Weisser A, La Rosee P, et al. Detection and quantification of residual disease in chronic myelogenous leukemia. Leukemia, 14: 998-1005, 2000.
73. Pallisgaard N, Clausen N, Schroder H, et al. Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript. Genes Chromosomes Cancer, 26: 355-365, 1999.
74. Krauter J, Wattjes MP, Nagel S, et al. Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21) -positive AML patients. Br J Haematol, 107: 80-85, 1999.
75. Gabert J, Beillard E, van der Velden VHJ, et al. Standardization and quality control studies of 'real-time' quantitative riverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - A Europe Against Cancer Program. Leukemia, 2003 Oct 9 [Epub ahead of print].
76. Beillard E, Pallisgaard N, van der Velden VHJ, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia, 2003 Oct 9 [Epub ahead of print].
77. Neale GA, Coustan-Smith E, Pan Q, et al. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia, 13: 1221-1226, 1999.
78. Veltroni M, De Zen L, Sanzari MC, et al., on behalf of the I-BFM-ALL-FCM-MRD-Study Group. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in ALL. Haematologica, 88: 1245-1252, 2003.
79. Malec M, Bjorklund E, Soderhall S, et al. Flow cytometry and allele-specific oligonucleotide PCR are equally effective in detection of minimal residual disease in ALL. Leukemia, 15: 716-727, 2001.
80. Munoz L, Lopez O, Martino R, et al. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia. Haematologica, 85: 704-710, 2000.
81. San Miguel JF, Parreira A, Wormann B, et al. Investigation of minimal residual disease in acute non-lymphoblastic leukemia: International standardization and clinical evaluation. In: European Union Biomedical and Health Research: the BIOMED-1 Programme. Ed. Baigs SS, Bardoux C, Fracchia GN, et al. IOS Press, Amsterdam, pp 372-373, 1995.
82. Saldanha J, Silvy M, Arlinghaus R et al. International reference biological standards for RQ PCR analysis of BCR ABL for therapeutic optimization. Blood, Proceedings of the American Society of Hematology (ASH) Meeting, 2003.
83. Lo Coco F, Diverio D, Avvisati G, et al: Therapy of molecular relapse in acute promyelocytic leukemia. Blood, 94: 2225-2229, 1999.
84. Cazzaniga G, Lanciotti M, Rossi V, et al. Prospective molecular monitoring of BCR/ABL transcript in children with Ph+ acute lymphoblastic leukaemia unravels differences in treatment response. Br J Haematol, 119: 445-453, 2002.
85. Scheuring UJ, Pfeifer H, Wassmann B, et al. Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571). Blood, 101: 85-90, 2003.
86. Biondi A, Rambaldi A, Rossi V, et al. Detection of ALL-1/AF4 fusion transcript by reverse transcription-polymerase chain reaction for diagnosis and monitoring of acute leukemias with the t(4;11) translocation. Blood, 82: 2943-2947, 1993.
87. Cimino G, Elia L, Rivolta A, et al. Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALL-1/AF-4 positive-acute lymphoblastic leukaemia. Br J Haematol, 92: 659-664, 1996.
88. Ida K, Taki T, Bessho F, et al. Detection of chimeric mRNAs by reverse transcriptase-polymerase chain reaction for diagnosis and monitoring of acute leukemias with 11q23 abnormalities. Med Pediatr Oncol, 28: 325-332, 1997.
89. Cimino G, Elia L, Rapanotti MC, et al. A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia. Blood, 95: 96-101, 2000.
90. Hunger SP, Fall MZ, Camitta BM, et al. E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood, 91: 1021-1028, 1998.
91. Cayuela JM, Baruchel A, Orange C, et al. TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia. Blood, 88: 302-308, 1996.
92. Nakao M, Yokota S, Horiike S, et al. Detection and quantification of TEL/AML1 fusion transcripts by polymerase chain reaction in childhood acute lymphoblastic leukemia. Leukemia, 10: 1463-1470, 1996.
93. Satake N, Kobayashi H, Tsunematsu Y, et al. Minimal residual disease with TEL-AML1 fusion transcript in childhood acute lymphoblastic leukaemia with t(12;21). Br J Haematol, 97: 607-611, 1997.
94. Zuna J, Hrusak O, Kalinova M, et al. TEL/AML1 positivity in childhood ALL: Average or better prognosis. Leukemia, 13: 22-24, 1999.
95. Foroni L, Harrison CJ, Hoffbrand AV, et al. Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis. Br J Haematol, 105: 7-24, 1999.
96. Van Dongen, JJ, Seriu, T, Panzer-Grumayer, ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet, 352: 1731-1738, 1998.
97. Cave H, van der Werff Ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med, 339: 591-598, 1998.
98. Jacquy C, Delepaut B, Van Daele S, et al. A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse. Br J Haematol, 98: 140-146, 1997.
99. Goulden N, Langlands K, Steward C, et al. PCR assessment of bone marrow status in 'isolated' extramedullary relapse of childhood B-precursor acute lymphoblastic leukaemia. Br J Haematol, 87: 282-285, 1994.
100. Biondi A, Valsecchi MG, Seriu T, et al. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM Study Group. Leukemia, 14: 1939-1943, 2000.
101. Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood, 96: 2691-2696, 2000.
102. Panzer-Grumayer ER, Schneider M, Panzer S, et al. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood, 95: 790-794, 2000.
103. Coustan-Smith E, Sancho J, Behm FG, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood, 100: 52-58, 2002.
104. Roberts WM, Estrov Z, Ouspenskaia MV, et al. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. New Engl J Med, 30: 317-323, 1997.
105. Neale GA, Menarguez J, Kitchingman GR, et al. Detection of minimal residual disease in T-cell acute relapse. Blood, 78: 739-747, 1991.
106. Dibenedetto SP, Lo Nigro L, Mayer SP, et al. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia. Blood, 90: 1226-1232, 1997.
107. Willemse MJ, Seriu T, Hettinger K, et al. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood, 99: 4386-4393, 2002.
108. Knechtli CJC, Goulden NJ, Hancock JP, et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood, 92: 4072-4079, 1998.
109. Bader P, Hancock J, Kreyenberg H, et al. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia, 16: 1668-1672, 2002.
110. van der Velden VH, Joosten SA, Willemse MJ, et al. Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia. Leukemia, 15: 1485-1487, 2001.
111. Goulden N, Bader P, Van Der Velden V, et al. Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia. Br J Haematol, 122: 24-29, 2003.
112. Knechtli CJ, Goulden NJ, Hancock JP, et al. Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia. Br J Haematol, 102: 860-871, 1998.
113. Bunin N, Johnston DA, Roberts WM, et al. Residual leukaemia after bone marrow transplant in children with acute lymphoblastic leukaemia after first haematological relapse or with poor initial presenting features. Br J Haematol, 120: 711-715, 2003.
114. van Rhee F, Marks DI, Lin F, et al. Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow. Leukemia, 9: 329-335, 1995.
115. Brisco MJ, Sykes PJ, Hughes E, et al. Monitoring minimal residual disease in peripheral blood in B-lineage acute lymphoblastic leukaemia. Br J Haematol, 99: 314-319, 1997.
116. Coustan-Smith E, Sancho J, Hancock ML, et al. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood, 100: 2399-2402, 2002.
117. van der Velden V, Jacobs DC, Wijkhuijs AJ, et al. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia, 16: 1432-1436, 2002. Eden T. Translation of cure for acute lymphoblastic leukaemia to all children. Br J Haematol, 118: 945-951, 2002.
118. van der Velden V, Jacobs DC, Wijkhuijs AJ, et al. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia, 16: 1432-1436, 2002. Eden T. Translation of cure for acute lymphoblastic leukaemia to all children. Br J Haematol, 118: 945-951, 2002.